Document is current
Any future updates will be listed below
-
Authors
Chatterjee, Aditi https://orcid.org/0000-0003-0595-3866
Mustafa Ali, Moaath K.
Bailey, Christopher M.
Liu, Yuchen
Small, Donald
Smith, Catherine C. https://orcid.org/0000-0003-0160-7026
Traer, Elie https://orcid.org/0000-0001-8844-2345
Wang, Yin https://orcid.org/0000-0002-4749-3768
Silvestri, Giovannino https://orcid.org/0000-0001-5911-6997
Baer, Maria R. https://orcid.org/0000-0002-9499-1348
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (BX005120)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA134274)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA006973)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA277031)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA271412)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA224019)
American Cancer Society (MRSG-17-040-01-LIB)
- License Information
-
More Information
Article History
Received: 20 November 2025
Revised: 3 April 2026
Accepted: 1 May 2026
First Online: 2 June 2026
Competing interests
: CCS reports research funding from Revolution Medicines, ERASCA, Abbvie; honoraria from Daiichi Sankyo; funding for clinical trials from Zentalis and Biomea; has served on advisory boards for Abbvie, Genentech, Servier and Biomea; and has served as a consultant for Astellas. ET reports research funding from AstraZeneca, Genentech, Prelude, Rigel, Schrodinger; funding for clinical trials from Incyte; and has served as a consultant for Abbvie, Astellas, Daiichi-Sankyo, Incyte, Rigel, Servier and Syndax.
